Chhattisgarh’s health authorities are taking decisive action to ensure the quality of medicines distributed throughout the state. A recent move involves issuing a show-cause notice to M/s. Effi Parenterals, with the intention of blacklisting them due to concerns about drug quality.
The health department mandates that all drug batches supplied to health institutions undergo thorough quality testing before distribution. This testing is carried out in NABL-accredited laboratories, focusing on ensuring the efficacy and safety of the medicines.
Specifically, samples of Albendazole tablets IP 400 mg (Drug Code – D12) from batches PGT25451, PGT25450, PGT25480, and PGT25229, supplied by M/s. Effi Parenterals, were tested at the State Drug Testing and Research Laboratory in Raipur. The results showed that these batches did not meet the required quality standards. As a result, the department initiated the process to blacklist the firm. Furthermore, the firm has been directed to retrieve the failed batches from all medicine warehouses.
It’s worth noting that prior to this, the firm had supplied 14 batches of Albendazole tablets IP 400 mg, which had passed the necessary tests and were subsequently distributed to health institutions.